GlassScriptPhysician profile
Matthew D Karam
NPI 1790993160
$130,927.56
in general payments reported to CMS, 2019-2025
5 companies · $626 in 2025
The $626 reported for 2025 was less than what a typical Orthopaedic Trauma provider received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $612 · 2021: $347 · 2022: $128K · 2023: $305 · 2024: $585 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339 · Acquisitions: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.79 |
| Acquisitions | $177.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $128,385.11 | 2019-2025 | Motoband, Na, Actis |
| Zimmer Biomet Holdings, INC. | $1,814.51 | 2019-2025 | Affixus, Arcos, Mymobility Platform |
| Philips North America LLC | $600.00 | 2020 | |
| Smith+Nephew, INC. | $127.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,869.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Karam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.